Cell cycle effects of the novel topoisomerase I inhibitor NU/ICRF 505 in a panel of chinese hamster ovary cell lines

This publication has 8 references indexed in Scilit:

• Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance
  Biochemical Pharmacology, 1996
• Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505
  British Journal of Cancer, 1996
• Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU / ICRF 500
  Mutation Research/Genetic Toxicology, 1995
• Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates
  Biochemical Pharmacology, 1995
• Higher G2 sensitivity to the induction of chromosomal damage in the CHO mutant EM9 than in its parental line AA8 by camptothecin, an inhibitor of DNA topoisomerase I
  Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1993
• Reduced topoisomerase II and elevated α class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C
  Biochemical Pharmacology, 1992
• The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells*1
  Experimental Cell Research, 1991
• Isolation and partial characterisation of a mammalian cell mutant hypersensitive to topoisomerase II inhibitors and X-rays
  Mutation Research/DNA Repair, 1990